A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Show Description +

David R. Chow, MD, FRCS(C), discusses a phase 3 PULSAR post hoc analysis of patients unable to maintain every 12-week or 16-week dosing with high-dose aflibercept.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

aflibercept

•

high-dose aflibercept

•

Regeneron Pharmaceuticals

•

Eylea

Up Next

Name: A Closer Look at 8 mg Aflibercept
Uploaded: 2023-08-08T15:31:56+00:00
Description: David R. Chow, MD, FRCS(C), discusses a phase 3 PULSAR post hoc analysis of patients unable to maintain every 12-week or 16-week dosing with high-dose aflibercept.

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Treating GA With ANX007

Jeffrey S. Heier, MD

Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

Back to All Videos

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

David R. Chow, MD, FRCS(C), discusses a phase 3 PULSAR post hoc analysis of patients unable to maintain every 12-week or 16-week dosing with high-dose aflibercept.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

aflibercept

•

high-dose aflibercept

•

Regeneron Pharmaceuticals

•

Eylea

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

A Closer Look at 8 mg Aflibercept

Up Next

A Closer Look at 8 mg Aflibercept

More From ASRS: 2023 Coverage